ME02599B - Dijagnostičko sredstvo interferon tipa 1 - Google Patents
Dijagnostičko sredstvo interferon tipa 1Info
- Publication number
- ME02599B ME02599B MEP-2017-24A MEP2417A ME02599B ME 02599 B ME02599 B ME 02599B ME P2417 A MEP2417 A ME P2417A ME 02599 B ME02599 B ME 02599B
- Authority
- ME
- Montenegro
- Prior art keywords
- interferon
- diagnostic
- type
- interferon diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23963009P | 2009-09-03 | 2009-09-03 | |
| EP10814513.7A EP2473636B1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
| PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02599B true ME02599B (me) | 2017-06-20 |
Family
ID=43649646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-24A ME02599B (me) | 2009-09-03 | 2010-09-02 | Dijagnostičko sredstvo interferon tipa 1 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120251546A1 (me) |
| EP (1) | EP2473636B1 (me) |
| JP (2) | JP5727484B2 (me) |
| KR (1) | KR20120101340A (me) |
| CN (1) | CN102753704A (me) |
| AU (1) | AU2010289383B2 (me) |
| BR (1) | BR112012004781A2 (me) |
| CA (1) | CA2772921A1 (me) |
| CY (1) | CY1118566T1 (me) |
| DK (1) | DK2473636T3 (me) |
| ES (1) | ES2613055T3 (me) |
| HR (1) | HRP20170091T1 (me) |
| HU (1) | HUE032917T2 (me) |
| LT (1) | LT2473636T (me) |
| ME (1) | ME02599B (me) |
| MX (1) | MX2012002640A (me) |
| PL (1) | PL2473636T3 (me) |
| PT (1) | PT2473636T (me) |
| RS (1) | RS55641B1 (me) |
| RU (1) | RU2012112802A (me) |
| SI (1) | SI2473636T1 (me) |
| SM (1) | SMT201700063B (me) |
| WO (1) | WO2011028933A1 (me) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005529599A (ja) * | 2002-06-11 | 2005-10-06 | アイダホ リサーチ ファウンデーション | ウィルス感染を検出するためのタイプｉインターフェロン誘導タンパク質 |
| CA2670897A1 (en) * | 2006-12-06 | 2008-06-12 | Barbara White | Methods of treating systemic lupus erythematosus |
| CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| AR086074A1 (es) * | 2011-04-26 | 2013-11-13 | Genentech Inc | Composiciones y metodo para tratar enfermedades autoinmunes |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| CN111494624A (zh) * | 2012-06-13 | 2020-08-07 | 阿斯特拉捷利康股份公司 | 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案 |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
| RU2756109C2 (ru) | 2016-03-10 | 2021-09-28 | Виела Байо, Инк. | Связывающие ilt7 молекулы и способы их применения |
| CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
| CA3128785A1 (en) * | 2019-02-15 | 2020-08-20 | Astrazeneca Ab | Type i interferon-mediated disorders |
| WO2021094378A1 (en) | 2019-11-11 | 2021-05-20 | Astrazeneca Ab | Type i interferon inhibition in systemic lupus erythematosus |
| EP4157873A2 (en) | 2020-05-29 | 2023-04-05 | Astrazeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| KR20230110304A (ko) | 2020-11-18 | 2023-07-21 | 아스트라제네카 아베 | 스테로이드 절약 |
| CA3216395A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| WO2022223770A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| EP4333877A1 (en) * | 2021-05-04 | 2024-03-13 | Viela Bio, Inc. | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| BR112023023391A2 (pt) | 2021-05-12 | 2024-01-23 | Astrazeneca Ab | Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico |
| CA3226744A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| WO2023057369A2 (en) | 2021-10-04 | 2023-04-13 | Astrazeneca Ab | Treatment of lupus |
| WO2024056631A1 (en) | 2022-09-14 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
| WO2024079241A1 (en) | 2022-10-13 | 2024-04-18 | Astrazeneca Ab | Treatment of lupus |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| ATE78262T1 (de) | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
| US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| JP2008500009A (ja) * | 2003-03-03 | 2008-01-10 | ジェネンテック・インコーポレーテッド | 全身性エリテマトーデスの治療のための組成物と方法 |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| ATE517920T1 (de) | 2003-04-23 | 2011-08-15 | Medarex Inc | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) |
| NZ547157A (en) | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
| CA2558808A1 (en) * | 2004-03-05 | 2005-09-22 | Rosetta Inpharmatics Llc | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| DK2662390T3 (da) | 2004-06-21 | 2017-11-06 | Squibb & Sons Llc | Interferon alpha receptor 1-antistoffer og anvendelse heraf |
| US20070092890A1 (en) * | 2005-08-05 | 2007-04-26 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
| WO2007123765A2 (en) * | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20100120627A1 (en) * | 2006-08-02 | 2010-05-13 | Abdelmajid Belouchi | Genemap of the human genes associated with psoriasis |
| CA2670897A1 (en) * | 2006-12-06 | 2008-06-12 | Barbara White | Methods of treating systemic lupus erythematosus |
| CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| AU2009212216B2 (en) * | 2008-02-08 | 2015-04-09 | Brigham And Women's Hospital, Inc. | Disease markers and uses thereof |
| CA2719078A1 (en) * | 2008-04-21 | 2009-10-29 | Witold Filipowicz | Antiviral therapy |
| US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
-
2010
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en active Application Filing
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Application Discontinuation
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-19 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2473636B1 (en) | 2016-10-26 |
| JP2015147788A (ja) | 2015-08-20 |
| JP5727484B2 (ja) | 2015-06-03 |
| PL2473636T3 (pl) | 2017-05-31 |
| HUE032917T2 (hu) | 2017-11-28 |
| RU2012112802A (ru) | 2013-10-10 |
| AU2010289383B2 (en) | 2015-04-16 |
| PT2473636T (pt) | 2017-02-06 |
| LT2473636T (lt) | 2017-02-10 |
| CA2772921A1 (en) | 2011-03-10 |
| ES2613055T3 (es) | 2017-05-22 |
| JP2013503642A (ja) | 2013-02-04 |
| US20150191788A1 (en) | 2015-07-09 |
| CY1118566T1 (el) | 2017-07-12 |
| US20160024205A1 (en) | 2016-01-28 |
| US20120251546A1 (en) | 2012-10-04 |
| RS55641B1 (sr) | 2017-06-30 |
| WO2011028933A1 (en) | 2011-03-10 |
| DK2473636T3 (en) | 2017-02-06 |
| EP2473636A1 (en) | 2012-07-11 |
| SI2473636T1 (sl) | 2017-04-26 |
| AU2010289383A1 (en) | 2012-04-19 |
| SMT201700063B (it) | 2017-03-08 |
| CN102753704A (zh) | 2012-10-24 |
| BR112012004781A2 (pt) | 2017-02-14 |
| EP2473636A4 (en) | 2013-02-27 |
| MX2012002640A (es) | 2012-06-25 |
| HRP20170091T1 (hr) | 2017-03-24 |
| KR20120101340A (ko) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02599B (me) | Dijagnostičko sredstvo interferon tipa 1 | |
| GB0913345D0 (en) | New combination 802 | |
| EP2513131A4 (en) | NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES | |
| GB0901941D0 (en) | 1007 | |
| GB0902804D0 (en) | Fusebox 2 | |
| GB0903160D0 (en) | Fusebox 4 | |
| GB0916350D0 (en) | Flexi-bend 2000 | |
| GB0921324D0 (en) | Guttergrow 2 | |
| GB0916463D0 (en) | Concept 40 | |
| GB0911961D0 (en) | Concept 48 | |
| GB0916451D0 (en) | Concept 31 | |
| GB0916452D0 (en) | Concept 32 | |
| GB0916453D0 (en) | Concept 33 | |
| GB0916455D0 (en) | Concept 34 | |
| GB0916456D0 (en) | Concept 35 | |
| GB0916457D0 (en) | Concept 36 | |
| GB0916460D0 (en) | Concept 37 | |
| GB0916461D0 (en) | Concept 38 | |
| GB0916462D0 (en) | Concept 39 | |
| GB0916475D0 (en) | Concept 54 | |
| GB0916464D0 (en) | Concept 43 | |
| GB0916465D0 (en) | Concept 44 | |
| GB0916449D0 (en) | Concept 30 | |
| GB0916448D0 (en) | Concept 23 | |
| GB0916447D0 (en) | Concept 22 |